Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Caffeine on the Narcoleptic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Case -group should be Narcoleptic with cataplexy~Exclusion Criteria:~* Individuals older than 45 years or younger than 18 years old.~* Individuals complaining of any diseases or conditions that affect their dietary intake, as such : renal failure, liver failure, malabsorption problems, cardiac diseases ... etc.~* Individuals having hypersensitivity to caffeine.~* Individuals with medical conditions that cause sleepiness (like hypothyroidism) and pregnant or lactating females will be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Caffeine (Type: EXPERIMENTAL): Caffeine is an adenosine receptor antagonist. It inhibits a part of the sleep cycle and, in turn, promotes the wakefulness state.~Generic name :Vivarin(1,3,7-trimethylxanthine), 200 mg/day for one week, Form of Administration:Oral in veg white capsule form (size 1) Drug Class:Central nervous system (CNS) stimulants.
- Fiber (Type: PLACEBO_COMPARATOR): Fiber powder will be used as placebo, Form of Administration:Oral in veg white capsule form (size 1)

Based on this trial design, predict the completion outcome and termination type (if applicable).